Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 5/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | HPGDS | O60760 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3246092 | 0.73 | MEN1 (0.39) | THRBSMN1; SMN2GPR119MAPT | |
| SCHEMBL3247572 | 0.73 | MEN1 (0.36) | THRBSMN1; SMN2GAAGPR119MAPT | |
| SCHEMBL3243016 | 0.72 | SMN1; SMN2 (0.37) | THRBSMN1; SMN2GAAGPR119MAPT | |
| SCHEMBL3250607 | 0.70 | GPR119 (0.38) | THRBSMN1; SMN2GAAGPR119LMNA | |
| SCHEMBL3247577 | 0.67 | MEN1 (0.36) | GPR119MAPTJAK2JAK1 | |
| SCHEMBL3557759 | 0.67 | GPR119 (0.57) | THRBSMN1; SMN2GAAGPR119LMNA | |
| SCHEMBL632936 | 0.66 | GPR119 (0.47) | THRBGPR119LMNAPOLBTP53 | |
| SCHEMBL5448476 | 0.65 | ALDH1A1 (0.43) | THRBSMN1; SMN2GAAGPR119LMNA | |
| SCHEMBL3253748 | 0.65 | ALDH1A1 (0.43) | THRBSMN1; SMN2GAAGPR119LMNA | |
| SCHEMBL3249302 | 0.64 | GPR119 (0.41) | THRBSMN1; SMN2GAAGPR119LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1799674-B1 | NEW PIPERIDINE ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-05-05 | — | — | EP | disclosed |
| US-20070173532-A1 | New Piperidine Antibiotics | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173532-A1 | New Piperidine Antibiotics | OPRM1, SIGMAR1, CBR3 | THRB 2100/4885SMN1; SMN2 2971/4885GAA 3929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.